NCT00471653 is a clinical trial of temozolomide in Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Who is sponsoring NCT00471653?

NCT00471653 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What drugs are being tested in NCT00471653?

Interventions in NCT00471653: temozolomide, comparative genomic hybridization, polymorphism analysis, laboratory biomarker analysis, pharmacological study, radiation therapy.

What condition does NCT00471653 study?

NCT00471653 studies Brain and Central Nervous System Tumors, Thrombocytopenia.

Is NCT00471653 still recruiting?

NCT00471653 is currently terminated. Last updated 9 July 2018.

Last reviewed 2018-07-09 · How we verify

NCT00471653

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

Terminated Last updated 9 July 2018

What this trial tests

trial testing temozolomide in Brain and Central Nervous System Tumors in 10 participants. Terminated before completion.

Timeline

11 November 2006

Primary endpoint
12 November 2008

18 August 2009

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	10
Start date	11 November 2006
Primary completion	12 November 2008
Estimated completion	18 August 2009
Sites	2 locations across United States

Drugs / interventions tested

temozolomide (temozolomide) — full drug profile →
comparative genomic hybridization
polymorphism analysis
laboratory biomarker analysis — full drug profile →
pharmacological study — full drug profile →
radiation therapy — full drug profile →

Conditions studied

Brain and Central Nervous System Tumors — all drugs for Brain and Central Nervous System Tumors →
Thrombocytopenia — all drugs for Thrombocytopenia →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →

Who can join

Adults 18 to 120, any sex, with Brain and Central Nervous System Tumors or Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Studying samples of blood in the laboratory from patients receiving temozolomide may help doctors learn how temozolomide works in the body. It may also help doctors learn more about how a patient's genes may affect the risk of developing thrombocytopenia. PURPOSE: This clinical trial is studying the pharmacokinetics in patients with newly diagnosed high-grade glioma receiving temozolomide and radiation therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of temozolomide

Trials testing the same drug.

NCT05052957 — hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) · Phase 2 · recruiting
NCT04566380 — ONO-4538 Phase II Rollover Study (ONO-4538-98) · Phase 2 · recruiting
NCT04400188 — A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cel · Phase 1, PHASE2 · completed
NCT03514069 — Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma · Phase 1 · active not recruiting
NCT02168270 — Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma · Phase 1 · terminated

Other recruiting trials for Brain and Central Nervous System Tumors

Currently open trials in the same condition.

NCT00978458 — Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · active not recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials

Trials by the same sponsor.

NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00471653 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 9 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00471653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing